ISPOR is hosting its next installment in its Signal Series on September 27th. In the talk, speakers will talk about economic evaluation of advanced therapy medicinal products (AMTPs). AMTPs include cell and gene therapies and often have a steep entry cost and uncertain long-term effects, which makes valuation difficult.
According to ISPOR, “Join us for the Signal event on September 27, 2022 to learn about the Danish experience with ATMP valuation approach and development of an innovative outcomes-based pricing agreement between pharma and payers. You will gain insight into the practicalities of stakeholder involvement and data requirements, and overall learnings from the outcomes-based pricing agreement experience from a multistakeholder perspective.”
To read more, click here.
(Source: ISPOR, September 1st, 2022)